{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:58:12Z","timestamp":1790236692146,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.nefroe.2024.12.001","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T20:11:32Z","timestamp":1736626292000},"page":"5-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Secondary hyperoxaluria: Cause and consequence of chronic kidney disease"],"prefix":"10.1016","volume":"45","author":[{"given":"Loreto","family":"Mariscal de Gante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Salanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariel","family":"Valdivia Mazeyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Serrano Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2024.12.001_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41581-022-00643-3","article-title":"Oxalate homeostasis","volume":"19","author":"Ermer","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0010","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.euf.2020.08.011","article-title":"Prevalence and trends in kidney stone among adults in the USA: analyses of national health and nutrition examination survey 2007-2018 data","volume":"7","author":"Abufaraj","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0015","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1089\/end.2015.0567","article-title":"Metabolic syndrome and kidney stone disease: a systematic review of literature","volume":"30","author":"Wong","year":"2016","journal-title":"J Endourol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.ajkd.2011.03.021","article-title":"Association between metabolic syndrome and the presence of kidney stones in a screened population","volume":"58","author":"Jeong","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0025","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.ajkd.2006.09.002","article-title":"Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study","volume":"48","author":"Lieske","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/00365590310008730","article-title":"Urinary stone disease in diabetes mellitus","volume":"37","author":"Meydan","year":"2003","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00240-021-01288-w","article-title":"Obesity-related indices and its association with kidney stone disease: a cross-sectional and longitudinal cohort study","volume":"50","author":"Lee","year":"2022","journal-title":"Urolithiasis"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0040","first-page":"2","article-title":"Dietary intake, absorption, metabolism, and excretion of oxalate","volume":"10","author":"Williams","year":"1990","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0045","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ekir.2018.07.020","article-title":"Secondary oxalate nephropathy: a systematic review","volume":"3","author":"Lumlertgul","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5527\/wjn.v4.i2.235","article-title":"Primary and secondary hyperoxaluria: understanding the enigma","volume":"4","author":"Bhasin","year":"2015","journal-title":"World J Nephrol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0055","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.bbadis.2012.03.004","article-title":"Primary hyperoxalurias: disorders of glyoxylate detoxification","volume":"1822","author":"Salido","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MNH.0000000000000229","article-title":"Oxalate, inflammasome, and progression of kidney disease","volume":"25","author":"Ermer","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0065","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1002\/j.2040-4603.2022.tb00199.x","article-title":"Oxalate flux across the intestine: contributions from membrane transporters","volume":"12","author":"Whittamore","year":"2021","journal-title":"Compr Physiol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1152\/ajprenal.90401.2008","article-title":"Ability of sat-1 to transport sulfate, bicarbonate, or oxalate under physiological conditions","volume":"297","author":"Krick","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0075","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/ng1762","article-title":"Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6","volume":"38","author":"Jiang","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0080","doi-asserted-by":"crossref","first-page":"G719","DOI":"10.1152\/ajpgi.00481.2005","article-title":"Ileal oxalate absorption and urinary oxalate excretion are enhanced in Slc26a6 null mice","volume":"290","author":"Freel","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1152\/ajprenal.00309.2018","article-title":"Characterization of renal NaCl and oxalate transport in Slc26a6-\/- mice","volume":"316","author":"Knauf","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00424-003-1090-3","article-title":"The SLC26 gene family of multifunctional anion exchangers","volume":"447","author":"Mount","year":"2004","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0095","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MNH.0b013e3282e7d7d0","article-title":"Renal physiology of SLC26 anion exchangers","volume":"16","author":"Sindi\u0107","year":"2007","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0100","series-title":"Hyperoxaluria","author":"Shah","year":"2023"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0105","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/ckj\/sfab145","article-title":"Oxalate nephropathy: a review","volume":"15","author":"Rosenstock","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0115","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2215\/CJN.01410308","article-title":"Determinants of 24-hour urinary oxalate excretion","volume":"3","author":"Taylor","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0120","first-page":"287","article-title":"Secondary hyperoxaluria due to pancreatic insufficiency","volume":"77","author":"de Martines","year":"2019","journal-title":"Neth J Med"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12882-023-03241-y","article-title":"Oxalate nephropathy in an elderly patient with newly diagnosed celiac disease - a case report","volume":"24","author":"Zijlstra","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/089277903321618743","article-title":"Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate","volume":"17","author":"Troxel","year":"2003","journal-title":"J Endourol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0135","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MNH.0000000000000518","article-title":"Enteric hyperoxaluria: role of microbiota and antibiotics","volume":"28","author":"Liu","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00240-015-0846-5","article-title":"The management of patients with enteric hyperoxaluria","volume":"44","author":"Asplin","year":"2016","journal-title":"Urolithiasis"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0145","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.kint.2017.11.011","article-title":"Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria","volume":"93","author":"Amin","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0150","series-title":"24-hour urine testing for nephrolithiasis: interpretation and treatment guidelines","author":"Leslie","year":"2024"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0155","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1681\/ASN.V1291986","article-title":"The primary hyperoxalurias","volume":"12","author":"Leumann","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0160","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","article-title":"Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment","volume":"27","author":"Cochat","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0165","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jamainternmed.2018.7980","article-title":"Association of urinary oxalate excretion with the risk of chronic kidney disease progression","volume":"179","author":"Waikar","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0170","unstructured":"Torres Ram\u00edrez A, Lorenzo Sellar\u00e9s V, Salido Ruiz E. Hiperoxaluria Primaria. In: Lorenzo Sellar\u00e9s V, L\u00f3pez G\u00f3mez JM (Eds). Nefrolog\u00eda al d\u00eda. 2659-2606. Available from: https:\/\/nefrologiaaldia.org\/es-articulo-hiperoxaluria-primaria-596."},{"key":"10.1016\/j.nefroe.2024.12.001_bib0175","doi-asserted-by":"crossref","first-page":"713","DOI":"10.5858\/arpa.2011-0565-RA","article-title":"Crystalline nephropathies","volume":"136","author":"Herlitz","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.semdp.2020.02.002","article-title":"A diagnostician\u2019s field guide to crystalline nephropathies","volume":"37","author":"Nicholas Cossey","year":"2020","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0185","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2362.1990.tb01900.x","article-title":"Hyperoxaluria or hypercalciuria in nephrolithiasis: the importance of renal tubular functions","volume":"20","author":"Lindsj\u00f6","year":"1990","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0190","series-title":"StatPearls [Internet]","article-title":"24-hour urine collection","author":"Corder","year":"2024"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0195","first-page":"306","article-title":"Kidney stone disease: an update on current concepts","volume":"4","author":"Alelign","year":"2018","journal-title":"Adv Urol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00864405","article-title":"Management of primary hyperoxaluria: efficacy of oral citrate administration","volume":"7","author":"Leumann","year":"1993","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0205","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ndt\/gfv005","article-title":"Enteric hyperoxaluria: an important cause of end-stage kidney disease","volume":"31","author":"Nazzal","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0210","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000030323","article-title":"Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria","volume":"61","author":"Takei","year":"1998","journal-title":"Urol Int"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0220","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.juro.2007.11.062","article-title":"Use of sevelamer hydrochloride as an oxalate binder","volume":"179","author":"Lieske","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0225","unstructured":"Lanthanum Carbonate (Fosrenol\u00ae) to Reduce Oxalate Excretion in Patients with Secondary Hyperoxaluria and Nephrolithiasis (LaCa). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03346369."},{"key":"10.1016\/j.nefroe.2024.12.001_bib0230","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000083560","article-title":"Importance of magnesium in absorption and excretion of oxalate","volume":"74","author":"Zimmermann","year":"2005","journal-title":"Urol Int"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0235","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000171511","article-title":"Bile acid malabsorption: mechanisms and treatment","volume":"13","author":"Eusufzai","year":"1995","journal-title":"Dig Dis"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0240","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0889-8529(02)00031-2","article-title":"Pathophysiology of hypocitraturic nephrolithiasis","volume":"31","author":"Hamm","year":"2002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0245","doi-asserted-by":"crossref","DOI":"10.3390\/nano11071763","article-title":"In search of an efficient complexing agent for oxalates and phosphates: a quantum chemical study","volume":"11","author":"Vekeman","year":"2021","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0250","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.34067\/KID.0001522020","article-title":"A prospective, double-blind, randomized, placebo-controlled, crossover study using an orally administered Oxalate Decarboxylase (OxDC)","volume":"1","author":"Quintero","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0255","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0260","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","article-title":"SGLT2 inhibitors in heart failure: targeted metabolomics and energetic metabolism","volume":"146","author":"Santos-Gallego","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0265","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.122.060402","article-title":"Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF","volume":"146","author":"Selvaraj","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0270","doi-asserted-by":"crossref","DOI":"10.15252\/msb.202110539","article-title":"An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria","volume":"18","author":"Lubkowicz","year":"2022","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0275","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.kint.2019.01.014","article-title":"Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases","volume":"96","author":"Mulay","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126204","article-title":"TRPV1 hyperfunction contributes to renal inflammation in oxalate nephropathy","volume":"22","author":"Lu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0285","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.kint.2016.03.035","article-title":"An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice","volume":"90","author":"Ludwig-Portugall","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0290","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","article-title":"Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug","volume":"11","author":"Idris","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0295","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.3405","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"5","author":"Xu","year":"2017","journal-title":"PeerJ"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0300","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1359\/jbmr.080514","article-title":"Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney","volume":"23","author":"Okada","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0305","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s00467-023-05917-x","article-title":"Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome","volume":"38","author":"Wannous","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefroe.2024.12.001_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106524","article-title":"Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation","volume":"186","author":"Anan","year":"2022","journal-title":"Pharmacol Res"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251424002359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251424002359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:23:31Z","timestamp":1744503811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251424002359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2013251424002359"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2024.12.001","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary hyperoxaluria: Cause and consequence of chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2024.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2024.06.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}